Maintenance — the sustained recomp protocol

Low-dose pulse, cycling rhythm, and what you run forever.

You finished Phase 2. Body composition shifted. Strength is up. IGF-1 is in the upper quartile. Now the actual question: what do you run for the next decade? Most people answer this wrong. They either ride the Phase 2 stack indefinitely until the pituitary stops responding, or they cliff-stop everything and watch recomp unwind in twelve weeks. Neither works. The sustained recomp protocol is its own thing — engineered around two biological constraints: receptor desensitization on the GH axis, and the fact that some compounds reward indefinite use while others punish it.

What's actually happening at the receptor level

Continuous GHRH stimulation downregulates pituitary somatotrophs. The practitioner corpus is explicit on this: GH secretagogues — CJC-1295, Ipamorelin, Tesamorelin, Hexarelin — must cycle because the pituitary desensitizes to continuous GHRH stimulation. More dose, less effect. This is not a theory; it is the pharmacology of the GHRH receptor. The receptor internalizes under sustained agonism. Eight-to-twelve weeks of pulsatile stimulation followed by a four-week washout restores receptor density and the next cycle hits like the first.

This is the opposite of regenerative compounds. BPC-157 has no receptor downregulation problem. Practitioner-tier evidence describes individuals running BPC-157 continuously for years without adverse events or efficacy decline. Same logic for TB-500 at maintenance dose: the actin regulation pathway TB-500 works through doesn't desensitize the way G-protein-coupled receptors do. Tissue repair compounds reward continuity. Pulse compounds reward intermittency. Treating both the same way is the most common maintenance error.

The third category is the longevity layer — Epitalon, MOTS-c, GHK-Cu. These run in short, intense pulses spaced months apart. The substrate describes Epitalon cycles of 10–20 days, two-to-three times per year (every four-to-six months). MOTS-c sits in a middle position: 3–5x weekly during active blocks, then long washouts. These aren't every-week compounds. They are quarterly resets.

The fourth lever is the supporting muscle-protein layer. IGF-1 LR3 cycles tight: 4 weeks on, 4 weeks off. Practitioners do not run LR3 continuously — the systemic IGF-1 elevation suppresses endogenous output and the receptor pool needs the off-window to resensitize. Likewise the GHRP family (GHRP-2, GHRP-6, Hexarelin) cycle 4–6 weeks on, 4 weeks off.

So maintenance is not "less Phase 2." Maintenance is a different protocol shape: one continuous regenerative spine, one pulsed GH axis on an 8/4 cadence, one quarterly longevity reset, and one optional muscle-protein cycle layered for re-comp blocks.

The sustained recomp stack

A leaner version — the "if I could only run four forever" approach — strips this down to BPC-157 (daily, continuous), TB-500 (weekly maintenance), the CJC-1295/Ipamorelin cycle (8 on / 4 off), and Epitalon (quarterly). Most of the recomp-preservation benefit is in those four. Add IGF-1 LR3, MOTS-c, and GHK-Cu when you are running a deliberate recomp push, not as background.

Timing rules that matter

• GH axis is morning-fasted and pre-bed. Ipamorelin pre-bed on an empty stomach stacks with natural slow-wave GH release. Two hours after the last meal, minimum.
• CJC-1295 DAC any time of day. 8+ day half-life makes timing essentially irrelevant — pick a fixed weekly slot for compliance.
• Progesterone and GH secretagogues separate by 4–6 hours. The substrate flags progesterone as blunting GH secretagogue effect when co-administered. GH compounds in the morning fasted; progesterone in the evening.
• BPC-157 is route-flexible. SubQ near the target tissue when local. Anywhere in the abdomen for systemic.
• Cycle off-windows are non-negotiable. Not "if I feel like it." The four-week washout is the entire reason the next eight-week block works.

What you should feel across the maintenance year

• Weeks 1–8 (GH block on): body composition holds or slightly improves, sleep architecture stays in the deeper-REM band, recovery between sessions is short, IGF-1 in the upper quartile.
• Weeks 9–12 (GH washout): subtle softening of recovery, sleep slightly less deep, IGF-1 drifting toward midrange. This is the receptor reset doing its job. Do not extend the cycle to avoid this — the washout is the work.
• Weeks 13–20 (next GH block on): the cycle hits as cleanly as the first. If it doesn't, your washout was too short.
• Quarterly Epitalon blocks (10–20 days): sleep quality reported as deeper and more consistent within days; effects often persist for weeks after the cycle ends.
• Continuous BPC-157 spine: joint comfort baseline holds. Gut function holds. No tolerance accrual reported in the practitioner corpus.

What's NOT happening on maintenance

• You are not chasing Phase 2 gains. Maintenance preserves the recomp delta. It does not stack new mass on top of it. Trying to do both at low dose produces neither.
• You are not "always on GH." Continuous GH-axis stimulation kills the GH axis. The washout is mandatory infrastructure, not a break.
• You are not running LR3 year-round. Year-round LR3 suppresses endogenous IGF-1 production. Pulse it during recomp blocks only.
• You are not doubling Epitalon to make it work faster. It is a pulse compound. The pulse is the protocol.
• You are not skipping bloodwork because "everything feels fine." IGF-1, fasting glucose, fasting insulin, HOMA-IR, lipids, and body composition (DEXA where available) on the same quarterly cadence as the Epitalon blocks. Lagging indicators tell you what feel cannot.
• You are not adding a new compound every quarter. Maintenance is the stable spine. New compounds belong to deliberate recomp blocks, not to background.

Research describes this. Track it. Adjust the cadence to your labs, not your impatience.